Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy
Conditions
Interventions
ETC-1002
Placebo
Locations
104
United States
Huntsville, Alabama, United States
Cottonwood, Arizona, United States
Phoenix, Arizona, United States
Canoga Park, California, United States
Santa Rosa, California, United States
Bridgeport, Connecticut, United States
Start Date
January 21, 2016
Primary Completion Date
February 21, 2018
Completion Date
March 28, 2018
Last Updated
May 11, 2020
NCT07473960
NCT00353782
NCT07037771
NCT07489209
NCT07487363
NCT07058077
Lead Sponsor
Esperion Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions